Vision via sound for the blind

Australian researchers have developed cutting-edge technology known as "acoustic touch" that helps people 'see' using sound. The technology has the potential to transform the lives of those who are blind or have low vision.

Around 39 million people worldwide are blind, according to the World Health Organisation, and an additional 246 million people live with low vision, impacting their ability to participate in everyday life activities.

The next generation smart glasses, which translate visual information into distinct sound icons, were developed by researchers from the University of Technology Sydney and the University of Sydney, together with Sydney start-up ARIA Research.

"Smart glasses typically use computer vision and other sensory information to translate the wearer's surrounding into computer-synthesized speech," said Distinguished Professor Chin-Teng Lin, a global leader in brain-computer interface research from the University of Technology Sydney.

"However, acoustic touch technology sonifies objects, creating unique sound representations as they enter the device's field of view. For example, the sound of rustling leaves might signify a plant, or a buzzing sound might represent a mobile phone," he said.

A study into the efficacy and usability of acoustic touch technology to assist people who are blind, led by Dr Howe Zhu from the University of Technology Sydney, has just been published in the journal PLOS ONE.

The researchers tested the device with 14 participants; seven individuals with blindness or low vision and seven blindfolded sighted individuals who served as a control group.

They found that the wearable device, equipped with acoustic touch technology, significantly enhanced the ability of blind or low-vision individuals to recognise and reach for objects, without causing too much mental effort.

"The auditory feedback empowers users to identify and reach for objects with remarkable accuracy," said Dr Zhu. "Our findings indicate that acoustic touch has the potential to offer a wearable and effective method of sensory augmentation for the visually impaired community."

The research underscores the importance of developing assistive technology in overcoming the challenges such as locating specific household items and personal belongings.

By addressing these day-to-day challenges, the acoustic touch technology opens new doors for individuals who are blind or have low vision, enhancing their independence and quality of life.

Read more at Science Daily

Scientists achieve promising results towards restoring vision in blindness caused by cellular degeneration in the eye

A preclinical study using stem cells to produce progenitor photoreceptor cells -- light-detecting cells found in the eye -- and then transplanting these into experimental models of damaged retinas has resulted in significant vision recovery. This finding, by scientists at Duke-NUS Medical School, the Singapore Eye Research Institute and the Karolinska Institute in Sweden, marks a first step towards potentially restoring vision in eye diseases characterised by photoreceptor loss.

"Our laboratory has developed a novel method that enables the production of photoreceptor progenitor cells resembling those in human embryos," said Assistant Professor Tay Hwee Goon, first author of the study from Duke-NUS' Centre for Vision Research. "Transplantation of these cells into experimental models has yielded partial restoration of the retinal function."

The degeneration of photoreceptors in the eye is a significant cause of declining vision that can eventually lead to blindness and for which there is currently no effective treatment. Photoreceptor degeneration occurs in a variety of inherited retinal diseases, such as retinitis pigmentosa -- a rare eye disease that breaks down cells in the retina over time and eventually causes vision loss -- and age-related macular degeneration, a leading cause of vision impairment worldwide.

Asst Prof Tay and her team developed a procedure to grow human embryonic stem cells in the presence of purified laminin proteins that are involved in normal development of human retinas. In the presence of the laminins, stem cells could be directed to differentiate into photoreceptor progenitor cells responsible for converting light into signals that are sent to the brain.

When these cells were transplanted into damaged retinas, the preclinical models showed significant recovery of vision. A diagnostic test called electroretinogram also identified significant recovery in the retinas via electrical activity in the retina in response to a light stimulus. The transplanted cells established connections with surrounding retinal cells and nerves in the inner retina. They also survived and functioned for many weeks after transplantation.

Moving forward, the team hopes to refine their method to make it simpler and achieve more consistent results than earlier attempts to explore stem cell therapy for photoreceptor cell replacement.

"It is exciting to find these results, which suggest a promising route towards using stem cells to treat those forms of visual deterioration and blindness caused by the loss of photoreceptors," said Dr Helder Andre, Head of Molecular and Cellular Research from Karolinska Institute's Department of Clinical Neuroscience and a senior author of the study.

Associate Professor Enrico Petretto, Director of the Centre for Computational Biology at Duke-NUS and the study's bioinformatics analysis lead, added: "Our method may also be useful for understanding the molecular and cellular pathways that drive the progression of macular degeneration, perhaps leading to the development of other therapeutic approaches."

The next challenge for the researchers is to explore the efficacy of their method in models of photoreceptor degeneration that more closely match the human condition.

"If we get promising results in our future studies, we hope to move to clinical trials in patients," said Professor Karl Tryggvason, from Duke-NUS' Cardiovascular and Metabolic Disorders Programme, and the corresponding author of the study. "That would be an important step towards for being able to reverse damage of the retina and restore vision."

Read more at Science Daily

How a single protein could unlock age-related vision loss

Research led by Sanford Burnham Prebys professor Francesca Marassi, Ph.D., is helping to reveal the molecular secrets of macular degeneration, which causes almost 90% of all age-related vision loss. The study, published recently in the Biophysical Journal, describes the flexible structure of a key blood protein involved in macular degeneration and other age-related diseases, such as Alzheimer's and atherosclerosis.

"Proteins in the blood are under constant and changing pressure because of the different ways blood flows throughout the body," says Marassi. "For example, blood flows more slowly through small blood vessels in the eyes compared to larger arteries around the heart. Blood proteins need to be able to respond to these changes, and this study gives us fundamental truths about how they adapt to their environment, which is critical to targeting those proteins for future treatments."

There are hundreds of proteins in our blood, but the researchers focused on vitronectin, one of the most abundant. In addition to circulating in high concentrations in the blood, vitronectin is found in the scaffolding between cells and is also an important component of cholesterol.

Vitronectin is a key player in many age-related diseases, but for Marassi's team, the most promising target is macular degeneration, which affects as many as 11 million people in the United States. This number is expected to double by 2050.

"This protein is an important target for macular degeneration because it accumulates in the back of the eye, causing vision loss. Similar deposits appear in the brain in Alzheimer's disease and in the arteries in atherosclerosis," says Marassi. "We want to understand why this happens and leverage this knowledge to develop new treatments."

To approach this question, the researchers were interested in learning how the protein changes its structure at different temperatures and under different levels of pressure, approximating what happens in the human body.

"Determining the structure of a protein is the most important part of determining its function," adds Marassi. Through detailed biochemical analysis, the researchers found that the protein can subtly change its shape under pressure. These changes cause it to bond more easily to calcium ions in the blood, which the researchers suggest leads to the buildup of calcified plaque deposits characteristic of macular degeneration and other age-related diseases.

"It's a very subtle rearrangement of the molecular structure, but it has a big impact on how the protein functions," says Marassi. "The more we learn about the protein on a structural and mechanistic level, the better chance we have of successfully targeting it with treatments."

These structural insights will streamline the development of treatments for macular degeneration because it will allow researchers and their partners in the biotech industry to custom-design antibodies that selectively block the protein's calcium binding without disrupting its other important functions in the body.

Read more at Science Daily